Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 4, 2007, Pages 185-191

  Takase, Hiromichi ^a   Hashimoto, Ayako ^a   Okutsu, Reiko ^a   Hirose, Yoshimi ^a   Ito, Hideki ^a   Imaizumi, Takashi ^a   Miyakoda, Goro ^a   Mori, Toyoki ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Adhesion molecules; Anti atherosclerosis agent; CAS 73963 72 1; Cilostazol, anti atherosclerotic effect, ApoE knockout mice; HDL cholesterol

Indexed keywords

APOLIPOPROTEIN E; CILOSTAZOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHODIESTERASE III INHIBITOR; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG TOLERABILITY; IN VITRO STUDY; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN;

EID: 34248173411     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296604     Document Type: Article

References (28)

1. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170:191-203.
2. Nakashima Y, Raines EW, Plump AS, Breslow, JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the apoE-deficient mouse. Arterioscler Thromb Vasc Biol. 1998;18:842-51.
3. Ramos CL, Huo Y, Jung U, Ghosh S, Manka DR, Sarembock IJ, et al. Direct demonstration of P-selectin- and VCAM-1-dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein E-deficient mice. Circ Res. 1999;84:1237-44.
4. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from framingham to the veterans affairs high-density lipoprotein intervention trial. Am J Cardiol. 2000;86 (Suppl 12A):19L-22L.
5. Assmann G, Gotto AM. HDL cholesterol and protective factors in atherosclerosis. Circulation. 2004;109 (Suppl 1): III8-14.
6. Choudhury RP, Rong JX, Trogan E, Elmalem VI, Dansky HM, Breslow JL, et al. Fallon JT, Fisher EA. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol. 2004;24:1904-9.
7. Rong JX, Li J, Reis ED, Choudhury RP, Dansky HM, Elmalem VI, et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation. 2001;104:2447-52.
8. Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, et al. Effects of the novel antiplatelet agent cilostazol on plasma lipoprotein in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998; 18:1942-7.
9. Regensteiner JG, Hiatt WR. Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med. 2002;112:49-57.
10. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, et al. Cilostazol stroke prevention study: a placebo-controlled double blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000;9:147-57.
11. Nishio Y, Kashiwagi A, Takahara N, Hidaka H, Kikkawa R. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells. Horm Metab Res. 1997;29:491-5.
12. Ollivier V, Parry GCN, Cobb RR, Prost D, Mackman N. Elevated cyclic AMP inhibits NF-kB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem. 1996;271:20828-35.
13. Pober JS, Slowik MR, De Luca LG, Ritchie AJ. Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1, but not intracellular adhesion molecule-1. J Immunol. 1993;150:5114-23.
14. Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kurabayashi M, et al. Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kB binding to its recognition sequence. Atherosclerosis. 2001;158:121-8.
15. Park SY, Lee JH, Kim YK, Kim CD, Rhim BY, Lee WS, et al. Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther. 2005;312:1241-8.
16. Tani T, Uehara K, Sudo T, Marukawa K, Yasuda Y, Kimura Y. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis. 2000;152:299-305.
17. Plump AS, Breslow JL. Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu Rev Nutr. 1995;15:495-518.
18. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic cells. Proc Natl Acad Sci. 1992;89:4471-5.
19. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68:231-40.
20. Akiyama H, Kudo S, Shimizu T. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Arzneimittel-Forschung (Drug Research). 1985;35:1124-32.
21. Oguchi S, Dimayuga P, Zhu J, Chyu KY, Yano J, Shah PK, et al. Monoclonal antibody against vascular cell adhesion molecule-1 inhibits neointimal formation after periadventitial carotid artery injury in genetically hypercholesterolemic mice. Arterioscler Thromb Vasc Biol. 2000;20:1729-36.
22. Lee JH, Oh GT, Park SY, Choi JH, Park JG, Kim CD, et al. Cilostazol reduces atherosclerosis by inhibition of super-oxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J. Pharmacol Exp Ther. 2005;313:502-9.
23. Yokoyama S. Assembly of high-density lipoprotein. Arterioscler Thromb Vasc Biol. 2006;26:20-7.
24. Olga S, Mazal BN, Yedida D, Gideon H, Yechwzkiel S. Macrophage cholesterol efflux to free apoprotein A-1 in C3H and C57BL/6 mice. Biochem Biophysic Res Commun. 2002;290:1376-81.
25. Van Eck M, Singaraja RR, Ye D, Hildebrand RB, James ER, Hayden MR, et al. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2006;26:929-34.
26. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96, 1221-32.
27. Massberg S, Brand K, Grüner S, Page S, Müller E, Müller I, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002;196, 887-96.
28. Ito H, Miyakoda G, Mori T. Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation. Platelets. 2004;15, 293-301.